Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

American Journal of Hypertension

Volumn 26, Issue 6, 2013, Pages 723-726

  Chatterjee, Ranee ^a,b   Thomas, Laine ^b   Svetkey, Laura ^a   Brancati, Frederick L ^c   Califf, Robert M ^a,d   Edelman, David ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; diabetes; hypertension; risk; serum potassium; valsartan.

Indexed keywords

POTASSIUM; VALSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

BLOOD PRESSURE; DIABETES; HYPERTENSION; RISK; SERUM POTASSIUM; VALSARTAN.;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CYCLOHEXANES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; POTASSIUM; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 84877781267     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt016     Document Type: Article

References (10)

1. Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS, Miller E, Brancati F. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2010; 170:1745-1751.
2. Heianza Y, Hara S, Arase Y, Saito K, Totsuka K, Tsuji H, Kodama S, Shieh SD, Yamada N, Kosaka K, Sone H. Low serum potassium levels and risk of type 2 diabetes: The Toranomon Hospital Health Management Center Study 1 (TOPICS 1). Diabetologia 2011; 54:762-766.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369:201-207.
4. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006; 48:219-224.
5. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-1490.
6. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30:e156-e166.
7. Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, Andres R. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106-111.
8. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29:498-502.
9. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99:1006-1012.
10. Hershon KS. Mechanistic and clinical aspects of renin- angiotensinaldosterone system blockade in the prevention of diabetes and cardiovascular disease. Endocr Pract 2011; 17:430-440.